Sandostatin Lar Depot Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
See Also
How Supplied
Manufacturer
Sandostatin Lar Depot Indications
Indications
Sandostatin Lar Depot Dosage and Administration
Adult
Children
Sandostatin Lar Depot Contraindications
Not Applicable
Sandostatin Lar Depot Boxed Warnings
Not Applicable
Sandostatin Lar Depot Warnings/Precautions
Warnings/Precautions
Sandostatin Lar Depot Pharmacokinetics
See Literature
Sandostatin Lar Depot Interactions
Interactions
Potentiates bromocriptine, CYP450 substrates (eg, quinidine, terfenadine), bradycardia-inducing drugs (eg, β-blockers, calcium channel blockers). Antagonizes cyclosporine. Not compatible with TPN solutions. May need to adjust antidiabetic agents. May affect agents used to control fluid and electrolyte balance. May interfere with efficacy of lutetium Lu 177 dotatate inj; discontinue octreotide at least 24 hours prior to each lutetium Lu dose.
Sandostatin Lar Depot Adverse Reactions
Adverse Reactions
Sandostatin Lar Depot Clinical Trials
See Literature
Sandostatin Lar Depot Note
Not Applicable
Sandostatin Lar Depot Patient Counseling
See Literature
Sandostatin Lar Depot Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
See Also
How Supplied
Manufacturer
Sandostatin Lar Depot Indications
Indications
Sandostatin Lar Depot Dosage and Administration
Adult
Children
Sandostatin Lar Depot Contraindications
Not Applicable
Sandostatin Lar Depot Boxed Warnings
Not Applicable
Sandostatin Lar Depot Warnings/Precautions
Warnings/Precautions
Sandostatin Lar Depot Pharmacokinetics
See Literature
Sandostatin Lar Depot Interactions
Interactions
Potentiates bromocriptine, CYP450 substrates (eg, quinidine, terfenadine), bradycardia-inducing drugs (eg, β-blockers, calcium channel blockers). Antagonizes cyclosporine. Not compatible with TPN solutions. May need to adjust antidiabetic agents. May affect agents used to control fluid and electrolyte balance. May interfere with efficacy of lutetium Lu 177 dotatate inj; discontinue octreotide at least 24 hours prior to each lutetium Lu dose.
Sandostatin Lar Depot Adverse Reactions
Adverse Reactions
Sandostatin Lar Depot Clinical Trials
See Literature
Sandostatin Lar Depot Note
Not Applicable
Sandostatin Lar Depot Patient Counseling
See Literature